JP2019524836A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524836A5
JP2019524836A5 JP2019508963A JP2019508963A JP2019524836A5 JP 2019524836 A5 JP2019524836 A5 JP 2019524836A5 JP 2019508963 A JP2019508963 A JP 2019508963A JP 2019508963 A JP2019508963 A JP 2019508963A JP 2019524836 A5 JP2019524836 A5 JP 2019524836A5
Authority
JP
Japan
Prior art keywords
unit dosage
dosage form
active agent
therapeutically active
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508963A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530173B2 (ja
JP2019524836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2017/050920 external-priority patent/WO2018033927A1/en
Publication of JP2019524836A publication Critical patent/JP2019524836A/ja
Publication of JP2019524836A5 publication Critical patent/JP2019524836A5/ja
Priority to JP2022099609A priority Critical patent/JP7546622B2/ja
Priority to JP2024016436A priority patent/JP7736834B2/ja
Application granted granted Critical
Publication of JP7530173B2 publication Critical patent/JP7530173B2/ja
Priority to JP2025076671A priority patent/JP2025114692A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508963A 2016-08-17 2017-08-17 活性薬剤の経口投与のための製剤 Active JP7530173B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022099609A JP7546622B2 (ja) 2016-08-17 2022-06-21 活性薬剤の経口投与のための製剤
JP2024016436A JP7736834B2 (ja) 2016-08-17 2024-02-06 活性薬剤の経口投与のための製剤
JP2025076671A JP2025114692A (ja) 2016-08-17 2025-05-02 活性薬剤の経口投与のための製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662375989P 2016-08-17 2016-08-17
US62/375,989 2016-08-17
PCT/IL2017/050920 WO2018033927A1 (en) 2016-08-17 2017-08-17 Formulations for oral administration of active agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022099609A Division JP7546622B2 (ja) 2016-08-17 2022-06-21 活性薬剤の経口投与のための製剤
JP2024016436A Division JP7736834B2 (ja) 2016-08-17 2024-02-06 活性薬剤の経口投与のための製剤

Publications (3)

Publication Number Publication Date
JP2019524836A JP2019524836A (ja) 2019-09-05
JP2019524836A5 true JP2019524836A5 (https=) 2020-09-17
JP7530173B2 JP7530173B2 (ja) 2024-08-07

Family

ID=61196521

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019508963A Active JP7530173B2 (ja) 2016-08-17 2017-08-17 活性薬剤の経口投与のための製剤
JP2022099609A Active JP7546622B2 (ja) 2016-08-17 2022-06-21 活性薬剤の経口投与のための製剤
JP2024016436A Active JP7736834B2 (ja) 2016-08-17 2024-02-06 活性薬剤の経口投与のための製剤
JP2025076671A Pending JP2025114692A (ja) 2016-08-17 2025-05-02 活性薬剤の経口投与のための製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022099609A Active JP7546622B2 (ja) 2016-08-17 2022-06-21 活性薬剤の経口投与のための製剤
JP2024016436A Active JP7736834B2 (ja) 2016-08-17 2024-02-06 活性薬剤の経口投与のための製剤
JP2025076671A Pending JP2025114692A (ja) 2016-08-17 2025-05-02 活性薬剤の経口投与のための製剤

Country Status (14)

Country Link
US (2) US12239691B2 (https=)
EP (1) EP3500291A4 (https=)
JP (4) JP7530173B2 (https=)
KR (4) KR20190039768A (https=)
CN (4) CN116831977A (https=)
AU (2) AU2017311698B2 (https=)
BR (1) BR112019003136A2 (https=)
CA (1) CA3033259A1 (https=)
IL (3) IL264880B2 (https=)
MX (1) MX2019001850A (https=)
NZ (1) NZ751668A (https=)
SG (1) SG11201901070YA (https=)
WO (1) WO2018033927A1 (https=)
ZA (1) ZA201901370B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113713090B (zh) 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
IL264880B2 (en) 2016-08-17 2024-09-01 Entera Bio Ltd Preparations for oral administration of active substances
AU2019385420A1 (en) * 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
EP4122483B1 (en) * 2020-03-18 2025-04-30 Xizang Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
CA3251862A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising an acid-neutralizing polymer for the oral administration of active agents
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
AU2023226092A1 (en) * 2022-02-24 2024-10-03 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
US6984728B2 (en) 1993-09-24 2006-01-10 Schering Corporation Recombinant infectious laryngotracheitis virus and uses thereof
CN1162917A (zh) 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物,用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1998009645A1 (en) 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
MXPA01008611A (es) 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
KR100788970B1 (ko) 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
EP1420827B8 (en) 2001-08-17 2009-12-23 Novartis AG 5-cnac as oral delivery agent for parathyroid hormone fragments
NZ532597A (en) 2001-11-13 2006-04-28 Emisphere Tech Inc Phenoxy amine compounds and compositions for delivering active agents
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
JP4417110B2 (ja) * 2001-12-19 2010-02-17 株式会社三和化学研究所 放出制御型成型品
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
US20070155664A1 (en) * 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口dds製剤
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
WO2006124047A2 (en) 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
BRPI0518125A (pt) * 2004-11-19 2008-10-28 Smithkline Beecham Corp produto farmacêutico
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
RU2469709C2 (ru) 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
US20070178155A1 (en) 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007121471A2 (en) 2006-04-18 2007-10-25 Emisphere Technologies, Inc. Dialkyl ether delivery agents
EP2079456B1 (en) * 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US20100303901A1 (en) 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
US20100285098A1 (en) 2007-09-11 2010-11-11 Haley Jeffrey T Adhering troches with santacid for treatment of throat esophagus and stomach
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー/エス ペプチド及び送達剤を含む錠剤製剤
US9803731B2 (en) 2014-04-24 2017-10-31 American Axle & Manufacturing, Inc. Actuator device having cam and follower and controller configured to employ rate-based methodology to identify positioning of follower on cam at predetermined location
EP2975118B1 (en) 2014-07-16 2016-08-24 Johann Wolfgang Goethe-Universität, Frankfurt am Main Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
CN113713090B (zh) 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
IL264880B2 (en) 2016-08-17 2024-09-01 Entera Bio Ltd Preparations for oral administration of active substances
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Similar Documents

Publication Publication Date Title
JP2019524836A5 (https=)
JP2023098946A5 (https=)
HRP20211077T1 (hr) Farmaceutski pripravci koji sadrže natrij-nitrit
JP2021523149A5 (https=)
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
JP2016516808A5 (https=)
JP2018533954A5 (https=)
JP2019529541A5 (https=)
JP2013139446A5 (https=)
JP2004534850A5 (https=)
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
JP2006506942A5 (https=)
JP2011026348A5 (https=)
ZA201901370B (en) Formulations for oral administration of active agents
WO2012090225A3 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
JP2022028975A5 (https=)
CA2507894A1 (en) Use of a ppar.alpha. agonist and metformin for decreasing the serum triglycerides
JP2019515033A5 (https=)
RU2004105844A (ru) Новое применение 2-[5-(4-фторфенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей
RU2011130246A (ru) Фитоэстрогенные композиции для предотвращения или лечения симптомов, связанных с менопаузой
JP2009511426A5 (https=)
JP2022503771A5 (https=)
JP2017514829A5 (https=)
JP2015524808A5 (https=)